Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status | Journal for ImmunoTherapy of Cancer
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
Overall survival (OS) curves in each gastric cancer (GC) pathological... | Download Scientific Diagram
Kaplan-Meier survival curves of a progression-free survival (PFS) and b... | Download Scientific Diagram
Adjuvant chemotherapy improves overall survival in patients with stage IB non-small cell lung cancer
Breast Cancer Survival Rates: Prognosis by Age, Race & More
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology
Frontiers | Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors
Overall survival rates of patients with lung cancer. Kaplan-Meier... | Download Scientific Diagram
Breast Cancer Survival Rates: Prognosis by Age, Race & More
Cancer - Our World in Data
Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis | Scientific Reports
Figure 1 from Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. | Semantic Scholar
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
The role of censoring on progression free survival: Oncologist discretion advised - ScienceDirect
Peregrine Pharmaceuticals, Inc. Drug Doubles Lung Cancer Survival in Trial | BioSpace
Kaplan-Meier curves for overall survival (A) and progression-free... | Download Scientific Diagram
Prognostic factors in epithelial ovarian cancer: A population-based study | PLOS ONE
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis - Katrin M. Sjoquist, Sarah J. Lord, Michael L. Friedlander, Robert John Simes, Ian C. Marschner,
Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as a